Relay Therapeutics Q3 net loss $65.7M ($0.54), cash runway into H2 2026, advances lirafugratinib and RLY-2608

Relay Therapeutics, Inc.

2023-Q3 EPS reported -$2.12 revenue$25,547,000

Net loss of $65.7M ($0.54/share) vs $84.2M loss ($0.76) in Q3 2022; revenue $25.2M from Genentech milestone.
Cash, equivalents, investments $810.6M; expects to fund operations into second half of 2026.
Lirafugratinib (RLY-4008): 35% ORR in FGFR2-fusion tumors, 40% ORR in FGFR2-altered HR+/HER2- breast cancer; pivotal CCA cohort fully enrolled.
Plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet in PI3Kα-mutant breast cancer by YE 2023; paused RLY-2139 (CDK2) development.
Paused near-term commercial readiness for CCA to focus on tumor-agnostic opportunity; next data/regulatory update in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Relay Therapeutics, Inc. reported the quarter ended September 30, 2023 results: revenue $25.2 million, net income $65.7 million, EPS $0.54.

Period: the quarter ended September 30, 2023
Revenue: $25.2 million
Net income: $65.7 million
EPS: $0.54
Result: reported results

Exact text from the filing

Therapeutics expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026. Revenue: Revenue was $25.2 million for the third quarter of 2023, as compared to $0.3 million for the third quarter of 2022. The increase was primarily due to the recognition of previously received milestone

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-058199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.